

Sim & McBurney

Patent and Trade Mark Agents

330 University Avenue
6th floor
Toronto, Canada
M5G 1R7

Telephone (416) 595-1155
Fax (416) 595-1163

MICHAEL I. STEWART
ROGER T. HUGHES, Q.C.
TONI POLSON ASHTON
JOHN H. WOODLEY
KENNETH D. MCKAY
TIMOTHY M. LOWMAN
STEPHEN M. LANE
ARTHUR B. RENAUD
STEPHEN J. PERRY
PATRICIA A. RAE
DAVID A. RUSTON
BARBARA J. MURCHIE
L.E. TRENT HORNE
LOLA A. BARTOSZEWICZ
KAMLEH J. NICOLA

GEOFFREY B.C. DE KLEINE
KIMBERLY A. MCMANUS
WENDY M. NOSS
MATTHEW D. POWELL
REBECCA M. EAGEN
COBY A.B. SCHNEIDER

SENIOR CONSULTANT
PETER W. MCBURNEY

TECHNICAL ASSISTANTS
MICHAEL S. COLUCCI, Ph.D.
ANDREW R.O. JONES, B.A., LL.B.
MARCO M. CLEMENTONI, B. MATH.
KENNETH M. T. MURPHY, B.Sc.E.
JEILAH Y. CHAN, B.Sc., LL.B.

Please Quote

Our ref. 1038-1268 MIS/ac

Your ref.

Writer's Ext. 239

E-mail: mistewart@sim-mcburney.com

April 26, 2004

VIA COURIER


Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

RE: U.S. Patent Application No. 10/663,722
Filing Date: September 17, 2003
Applicant: George A. Cates et al.
Title: MULTIVALENT IMMUNIGENIC COMPOSITION CONTAINING
RSV SUBUNIT COMPOSITION AND INFLUENZA VIRUS
PREPARATION


Please find enclosed an Information Disclosure Statement and copies of the references listed therein with respect to each of the references cited in the specification, in the International Search Report received on the corresponding International application and in prior U.S. application No. 09/213,770.

Respectfully submitted,



Michael I. Stewart
Registration No. 24,973

M.I. Stewart/ac
Enclosures

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-1268 MIS:ac	SERIAL NO. 10/663,722
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		APPLICANT GEORGE A. CATES et al	
		FILING DATE September 17, 2003	GROUP 1642

U.S. PATENT DOCUMENTS

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
	5,494,673	Feb. 27/96				
	5,612,037	Mar. 18/97				
	5,911,998	Jun. 15/99				
	6,020,182	Feb. 1/00				

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION YES NO
	WO 95/02628	Jan. 26/95				
	WO 96/33738	Oct. 31/96				
	WO 95/34308	Dec. 21/95				
	WO 95/34323	Dec. 21/95				
	WO 98/02457	Jan. 22/98				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1. Glezen, W.P., et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level (1981). Vol. 98, pp. 708-715.
	2. Chanock, R.M., Serious respiratory track disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization (1992) Vol. 90, pp.137-142.
	3. Martin, A.J. et al. Epidemiology of respiratory viral infection among paediatric inpatients over six-year period in north-east England (1978), pp. 1035-1038.
	4. Robbins, A., and Freeman, P. Obstacles to developing vaccines for the third world. (1988) 259, 126-133.
	5. Glezen, W.P., et al. Risk of primary infection and reinfection with respiratory syncytial virus. (1986) 140, pp. 543-546.
	6. Katz, S.L. Prospects for immunizing against respiratory syncytial virus. Vol. 1. Washington: National Academic Press. (1985) pp. 397-409.
	7. Wertz, G.W., Sullender, W.M. Approaches to immunization against respiratory syncytial virus (1992) Vol. 20, pp.151-176.
	8. McIntosh, K. and Chanock, R.M. Respiratory syncytial virus. (1990) pp. 1045-1075.
	9. Murry AR, Dowell SF, 1997. Respiratory syncytial virus: not just for kids. Hosp. Pract. (Off Ed) 1997 Jul. 15; 32(7): 87-8, 91-4.
EXAMINER:	DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 1038-1268 MIS:ac	SERIAL NO. 10/663,772
	APPLICANT GEORGE A. CATES et al	
	FILING DATE September 17, 2003	GROUP 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		10. Mlinaric-Galinovic G, Falsey AR, Walsh EE, 1996. Respiratory syncytial virus infection in the elderly. 1996. 15, pp. 777-781
		11. Collins, P., et al. Respiratory syncytial Virus. (1996) pp.1313-1351.
		12. Walsh, E.E., Hall, Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. (1987) Vol. 155, pp.1198-1204.
		13. Walsh, E.E., Hruska, J. Monoclonal antibodies to respiratory syncytial virus proteins: Identification of the fusion protein. (1983) Vol. 47, pp. 171-177.
		14. Levine, S., et al. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus (1987) Vol. 69, pp. 2521-2524.
		15. Anderson, L.J., et al. Antigenic Characterization of respiratory syncytial virus strains with monoclonal antibodies (1985), Vol. 151, pp.626-633.
		16. Johnson, P.R., et al. Antigenic Relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B.... (1987) Vol. 61 (10), pp.3163-3166.
		17. Cherrie, A.H., et al. Human cytotoxic T cell stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. (1992) J. Virology 66, 2102-2110.
		18. Kim, H.W., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine (1969) Vol 89, 422-434.
		19. Friedewald, W.T., et al. Low-temperature-grown RS virus in adult volunteers. (1968) Vol. 204, pp. 142-146.
		20. Walsh, E.E., et al. Purification and characterization of the respiratory syncytial virus fusion protein. (1985) Vol. 66, pp. 409-415.
		21. Walsh, E.E., et al. Purification and characterization of GP90, One of the envelope glycoproteins of respiratory syncytial virus. (1984) Vol. 65, 761-766.
		22. Routledge, E.G., The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice. (1988) Vol. 69, 293-303.
		23. Fulginiti, V.A., et al. Respiratory Virus Immunization. (1969) Vol. 89 (4), pp. 435-448.
		24. Chin, J., et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population (1969) Vol. 89 (4), pp. 449-463.
		25. Kapikian, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) (1969) Vol. 89 (4), pp. 405-421.
		26. Kim, H.W., et al. Clinical and Immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. (1971), Vol 48, pp. 745-755.
		27. Wright, P.F., et al. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children (1982) Vol. 37 (1), pp. 397-400.
		28. Wright, P.F., et al. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants.(1976) Vol. 88, pp.931-936.
EXAMINER:		DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 1038-1268 MIS:ac	SERIAL NO. 10-663,722
	APPLICANT GEORGE A. CATES et al	
	FILING DATE September 17, 2003	GROUP 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		29. Belshe, R.B., Parenteral administration of live respiratory syncytial virus vaccine; results of a field trial. (1982) Vol. 145, pp 311-319.
		30. Murphy, B.R., et al. Dissociation between serum neutralizing and glycoprotein antibody response of infants and children who received inactivated respiratory syncytial virus vaccine(1986), 24(2), 197-202.
		31. Connors, M., et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia -RSV recombinants or RSV. (1992) Vol. 10, pp. 475-484.
		32. Prince, G.A., et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. (1986) Vol. 57 (3), pp. 721-728.
		33. Piedra, P.A., et al. Immune response to experimentally induced infection with respiratory syncytial virus: Possible role in the development of pulmonary disease. (1989) Vol. 70, pp. 325-333.
		34. Payne G.L., et al. Vaccine Vol. 16. pp. 92-98 1998.
		35. Fattom Ali et al. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. (1999) Vol. 17 pp. 126-133
		36. Ambrosch F. et al., Combined vaccination against yellow fever a comparative trial. 1994 Vol. 12 pp. 625-628.
		37. Frey Sharon et al. Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/Hepatitis B Vaccine 1999; 180 pp. 2018-2022.
		38. Insel, A. Richard., Potential alterations in Immunogenicity by Combining or Simultaneously Administering Vaccine Components. pp. 35-47.
		39. Plotkin A.S. et al. Vaccines. Third Edition pp. 508-530.
EXAMINER:	DATE CONSIDERED:	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.